N.E.W. Advisory Services’s Oramed Pharmaceuticals ORMP Stock Holding History

N.E.W. Advisory Services’s Portfolio ORMP Stock Details ORMP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$11.7K	Buy	3,429 +229	+7%	+$777	﹤0.01%	598
2025 Q4	$9.12K	Buy	+3,200	New	+$8.25K	﹤0.01%	630
2025 Q2	–	Sell	-18,900	Closed	-$40.4K	–	897
2025 Q1	$40.4K	Buy	18,900 +6,540	+53%	+$15.1K	﹤0.01%	390
2024 Q4	$29.9K	Hold	12,360	–	–	﹤0.01%	187
2024 Q3	$30.2K	Hold	12,360	–	–	﹤0.01%	183
2024 Q2	$31.8K	Sell	12,360 -600	-5%	-$1.43K	﹤0.01%	180
2024 Q1	$37.8K	Hold	12,960	–	–	﹤0.01%	172
2023 Q4	$29.9K	Hold	12,960	–	–	﹤0.01%	162
2023 Q3	$33.8K	Buy	+12,960	New	+$40.8K	﹤0.01%	151

Other funds holding ORMP

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

Aquamarine Financial George Town $1.37B AUM

Mercer Global Advisors Denver, Colorado $67.6B AUM 18.3% 1-Year Est. Return

GIA

Gem Investment Advisors Teaneck, New Jersey $102M AUM

Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

N.E.W. Advisory Services's ORMP Position: Q1 2026 in Review

N.E.W. Advisory Services increased its Oramed Pharmaceuticals (ORMP) stake by 7.2% in Q1 2026, buying an estimated $777 and bringing the position to 3,429 shares worth $11.7K. The position accounts for ﹤0.01% of the portfolio, ranked #598.

N.E.W. Advisory Services first reported a position in ORMP in Q3 2023 and has held it in 9 quarters since. The position peaked at $40.4K in Q1 2025. 64 funds tracked by Wall St. Rank hold ORMP as of Q1 2026.

N.E.W. Advisory Services held 3,429 shares of Oramed Pharmaceuticals worth $11.7K as of Q1 2026.
N.E.W. Advisory Services bought 229 Oramed Pharmaceuticals shares in Q1 2026, an estimated $777.
Oramed Pharmaceuticals made up ﹤0.01% of N.E.W. Advisory Services's portfolio in Q1 2026, its #598 holding.
N.E.W. Advisory Services first reported a position in Oramed Pharmaceuticals in Q3 2023 and has held it in 9 quarters since.
N.E.W. Advisory Services's Oramed Pharmaceuticals position peaked at $40.4K in Q1 2025.
64 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q1 2026.

Based on N.E.W. Advisory Services's 13F filing for Q1 2026, filed 5 May 2026.